Independent Financial Group LLC Makes New Investment in Globus Medical, Inc. $GMED

Independent Financial Group LLC acquired a new stake in shares of Globus Medical, Inc. (NYSE:GMED) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 8,760 shares of the medical device company’s stock, valued at approximately $755,000.

Other large investors have also made changes to their positions in the company. Advisory Services Network LLC acquired a new stake in shares of Globus Medical in the third quarter worth $26,000. EverSource Wealth Advisors LLC lifted its position in Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 197 shares during the period. SBI Securities Co. Ltd. lifted its position in Globus Medical by 98.2% during the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 167 shares during the period. Parallel Advisors LLC boosted its holdings in Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after purchasing an additional 173 shares during the last quarter. Finally, Headlands Technologies LLC boosted its holdings in Globus Medical by 485.4% in the second quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock valued at $45,000 after purchasing an additional 631 shares during the last quarter. 95.16% of the stock is owned by hedge funds and other institutional investors.

Globus Medical Stock Performance

GMED stock opened at $75.99 on Wednesday. Globus Medical, Inc. has a one year low of $51.79 and a one year high of $101.40. The firm’s fifty day moving average is $79.82 and its 200 day moving average is $86.29. The firm has a market cap of $10.31 billion, a PE ratio of 17.67, a P/E/G ratio of 1.57 and a beta of 0.95.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The business had revenue of $759.85 million during the quarter, compared to the consensus estimate of $740.35 million. During the same quarter in the prior year, the firm posted $0.68 earnings per share. The company’s revenue was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Research analysts predict that Globus Medical, Inc. will post 4.74 earnings per share for the current fiscal year.

Insider Buying and Selling at Globus Medical

In related news, Director David D. Davidar sold 25,000 shares of Globus Medical stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $80.76, for a total value of $2,019,000.00. Following the completion of the transaction, the director owned 510,175 shares in the company, valued at $41,201,733. The trade was a 4.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 18.38% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Weiss Ratings reiterated a “hold (c+)” rating on shares of Globus Medical in a research note on Monday, July 13th. Stifel Nicolaus decreased their price objective on Globus Medical from $95.00 to $80.00 and set a “hold” rating for the company in a report on Wednesday, July 8th. Wall Street Zen downgraded Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Piper Sandler dropped their target price on Globus Medical from $115.00 to $100.00 and set an “overweight” rating on the stock in a report on Monday, June 15th. Finally, Truist Financial reduced their price target on Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Thursday, July 16th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, Globus Medical has an average rating of “Moderate Buy” and a consensus price target of $103.75.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.